@article{Lees_C-2020_9593,
title = {COVID-19 and IBD drugs: should we change anything at the moment?},
author = {Lees, C. and Irving, P. and Beaugerie, L.},
month = {nov},
year = {2020},
abstract = {The COVID-19 pandemic has raised questions about the management of people with inflammatory bowel disease (IBD).To date, there have been over 43 million confirmed cases of COVID-19 globally, including over 1.1 million deaths (https://COVID-19.who.int). What have we learnt about the risks of SARS-CoV-2 infection in patients with IBD and is there any evidence to support a change in IBD management?},
pages = {632-634},
volume = {70},
issue = {4},
journal = {Gut},
publisher = {BMJ Publishing Group},
url = {https://doi.org/10.1136/gutjnl-2020-323247},
}
